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Abstract
Purpose This 2-year analysis assessed frequency of comorbidities and comorbidity screening in the Somatuline® (lanreotide,
LAN) Depot for Acromegaly (SODA) registry.
Methods Patient data collected included pituitary hormone deﬁciencies, sleep studies, echocardiograms, gallbladder
sonographies, colonoscopies, and glycated hemoglobin (HbA1c) levels. Insulin-like growth factor-1 (IGF-1) and growth
hormone levels in patients with (DM) and without (non-DM) diabetes mellitus were analyzed.
Results There were 241 patients enrolled. Pituitary hormone deﬁciencies were reported more frequently at enrollment in
male (56.9%) vs female patients (32.0%; p < 0.001). TSH deﬁciency was the most common endocrine deﬁciency (69.8%),
followed by gonadotropin deﬁciency (62.3%). Screening tests reported at enrollment: sleep studies in 29.9% (79.2% had
sleep apnea), echocardiogram in 46.1% (46.8% abnormal), gallbladder sonography in 18.7% (17.8% had gallstones), and
colonoscopy in 48.1% (35.3% had polyps). Follow-up studies were reported less frequently at 1 and 2 years. HbA1c data
were reported in 30.8% and 41.2% after 1 and 2 years. HbA1c levels were similar at 1 and 2 years of LAN therapy among
DM and non-DM patients with available data. Fewer DM vs non-DM patients achieved IGF-1 below upper limit of normal
at Month 24 (58.3% vs 80.6%; p= 0.033).
Conclusions Fewer than half of patients in SODA had screening results reported at enrollment for sleep apnea, cardio-
myopathy, and colon polyps. Gallbladder imaging was reported in a minority of patients. Lower IGF-1 control rates were
observed in DM vs non-DM patients at Month 24. These data suggest a need for better monitoring of comorbidities in US
acromegaly patients.
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Introduction
Although acromegaly is a rare disease (United States [US]
incidence was 11 cases per million person-years and pre-
valence was ~78 cases per million per year across
2008–2012) [1], the considerable burden of coexisting
comorbidities and increased mortality represents a major
medical problem [2–9]. Comorbidities signiﬁcantly increase
the odds of hospitalization and pharmacotherapy cost [10,
11]. Adequate management of acromegaly, including bio-
chemical control and treatment of its major comorbidities,
lowers the risk of mortality to the level of the general
population [12–16], and may reduce healthcare utilization
and cost associated with comorbidities [10, 11].
The Somatuline® (lanreotide) Depot for Acromegaly
(SODA) registry is a post-marketing, multicenter, observa-
tional study of patients treated with lanreotide depot (LAN)
in academic and private centers in the US (MS319, Clin-
icalTrials.gov Identiﬁer: NCT00686348). Previous analyses
of SODA have assessed the effectiveness, safety, and con-
venience of LAN in the treatment of acromegaly [17, 18].
Data from a 1-year analysis of the SODA registry showed
that hormonal control was achieved independently of drug
injection method, and patients found greater convenience
with the use of self- or partner-injections [17]. A follow-up
2-year analysis showed that the majority of patients (54.8%)
achieved both IGF-1 concentrations below upper limit of
normal (<ULN) and GH levels ≤ 2.5 µg/L [18]. Disease
control, deﬁned as GH < 1.0 µg/L, was achieved in 61.4%
of patients. Treatment-emergent adverse events (AEs) were
reported in 54.4% of patients. The AE proﬁle associated
with LAN therapy was similar to the known safety proﬁle of
LAN and the somatostatin receptor ligands (SRLs).
Retrospective studies still show an ~70% increase in
average standardized mortality rates in acromegaly patients
compared with the general population [14, 15]. Therefore,
addressing comorbidities is an important treatment goal.
Various acromegaly treatment guidelines recommend eval-
uating all patients for associated comorbidities such as
hypertension, diabetes mellitus (DM), cardiovascular dis-
ease, osteoarthritis, and sleep apnea, and include recom-
mendations on managing comorbidities [2–7]. Screening for
colon neoplasia, thyroid nodularity, and hypopituitarism is
also recommended. For patients receiving SRLs, only those
who develop signs and symptoms of gallstone disease
should undergo abdominal ultrasound, and thus routine
monitoring is not considered necessary [6]. Despite the
availability of guidelines, the frequency with which clin-
icians screen and monitor comorbid conditions outside of
controlled clinical trial settings is not well known. Using
data from the SODA registry, the objective of this analysis
was to summarize the frequency in which patients were
assessed for acromegaly comorbidities in the US.
Patients and methods
Study design and patient population
Details of the SODA study design and patient population
have been published previously [17, 18]. In brief, the
patients were eligible for inclusion if they had a clinical
diagnosis of acromegaly and either received LAN as their
ﬁrst medical therapy or were transitioned from other
somatostatin analogs. The SODA study was conducted in
accordance with the International Conference on Harmo-
nisation Good Clinical Practice, current Food and Drug
Administration regulations and guidelines, and local ethical
and legal requirements. All data collection, transmission,
and storage complied with the US Code of Federal Reg-
ulations and the Health Insurance Portability and
Accountability Act. Signed informed consent was obtained
from each patient at study inclusion.
Demographics, clinical characteristics, and comorbidities
listed in the patient medical history were collected at
enrollment. Patients could be enrolled before or after start-
ing LAN. Pituitary hormonal deﬁciencies were reported by
the investigator using a checkbox format for ACTH, ADH,
TSH, and gonadotropin deﬁciencies. Menstrual cycle and
menopausal status were not recorded. Hypopituitarism was
deﬁned as a deﬁciency in ≥1 of the 4 recorded pituitary
hormonal deﬁciencies. Data from optional speciality
tests, including sleep study, echocardiogram, gallbladder
sonography, and colonoscopy were recorded as obtained
during clinic visits at the discretion of the treating
physician. Biochemical control [18] was assessed using
serum IGF-1 and random serum GH levels (both evaluated
mostly at local laboratories). Since serum GH levels at
enrollment were not uniformly available, GH control was
only assessed at Month 12 (M12) and M24 and only for
patients not on pegvisomant. Control of glucose home-
ostasis was assessed using glycated hemoglobin (HbA1c)
levels, when available, at thresholds of <5.7% (in reference
range), 5.7%–6.4% (pre-DM), and ≥6.5% (DM). Since
HbA1c levels at enrollment were not uniformly available,
HbA1c control was assessed at M12 and M24 only. A
patient was deﬁned as having diabetes based on medical
history, anti-diabetic medication use, and/or HbA1c
level ≥6.5%.
Statistical analysis
Data for this analysis reﬂect an interim cut-off as of 29
September 2014. Continuous data were analyzed using
descriptive statistics (mean, median, and standard devia-
tions). Student’s t-tests were performed for exploratory
purposes. Categorical data were described by frequencies
and by chi-square or Fisher’s exact test probabilities, also
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performed for exploratory purposes. Probability tests of
categorical data are considered to be chi-square unless noted
otherwise. A two-sided p < 0.05 was considered signiﬁcant.
P-values were not adjusted for multiple comparisons. The
study population included all patients who received a dose
of study drug. This was an observational study, and thus the
frequency of study visits and assessments occurred at the
discretion of the clinician, which resulted in different sets of
patients across visits (unpaired) and reﬂected the availability
of reported data.
Results
As of 29 September 2014, 241 patients were enrolled and
included in the 2-year dataset [18]. Sixty-one patients were
<40 years of age, 124 were 40–60 years of age, and 56
were >60 years of age. Acromegaly was caused by pituitary
adenoma in 97% of patients (233/241); 8 patients had
other causes, including tumor not identiﬁed (n= 2),
tumor secreting GH-releasing hormone (n= 1), McCune-
Albright syndrome (n= 1), and cause not speciﬁed
(n= 4). The median time since acromegaly diagnosis was
4.3 years (quartile [Q]1= 1.71 years, Q3= 9.25). Addi-
tional demographic and clinical characteristics of the 2-year
SODA population can be found in the report by Salvatori
et al [18].
Patient comorbidities at enrollment are summarized in
Table 1. Almost half (48.6%) of patients at enrollment had
cardiovascular comorbidities, with hypertension being most
prevalent (45.2%). DM was present in 25.3% of patients at
enrollment. Despite the slight predominance of female
patients with acromegaly in SODA, one or more pituitary
hormone deﬁciencies were reported more frequently at
enrollment in male (66/116, 56.9%) vs female patients (40/
125, 32.0%; p < 0.001) (Table 1). Details regarding speciﬁc
hormone deﬁciencies were available in 106 patients with
hypopituitarism; most had single hormone deﬁciencies (61/
106, 57.5%), while 25.5% (27/106), 13.2% (14/106), and
3.8% (4/106) had 2, 3, and 4 hormone deﬁciencies,
respectively. TSH deﬁciency was the most common pitui-
tary hormone dysfunction (69.8%, 74/106). Gonadotropin
deﬁciency was reported in 66 of the patients with hypopi-
tuitarism (62.3%; 66/106): 57 males (86.4%; 57/66) and 9
(13.6%; 9/66) females (p < 0.001). Of the 125 females in the
study, only 9 (7.2%) were reported to have gonadotropin
deﬁciency and of these, 5 were treated with estrogen. The
rates of reported gonadotropin deﬁciency were similar
between women above age 50 (7%; 5/71) and below age 50
(7.4%; 4/54). Adrenocorticotropic hormone (ACTH) deﬁ-
ciency occurred in 28 patients. Of the 241, 5 (2.1%) patients
had diabetes insipidus, and all 5 had previous pituitary
surgery.
Data from the optional speciality tests conducted at
enrollment and during SODA and assessments of glucose
homeostasis during SODA are shown in Fig. 1.
Screening for sleep apnea: sleep study
At the enrollment visit, 29.9% of patients (72/241) had a
sleep study recorded, with the majority of these showing
sleep apnea (Fig. 1a). At M12 and M24, 2.5% (4/157) and
2.8% (3/109) of patients had a sleep study (new screenings
each, not follow-up), respectively, with 100% showing
sleep apnea.
Screening for cardiac abnormalities:
echocardiogram
At enrollment, 46.1% of patients (111/241) had an echo-
cardiogram; nearly one-half of these (46.8%, 52/111) were
abnormal (Fig. 1b). Abnormalities included ventricular
hypertrophy/enlargement in 19.8% (22/111), valve dis-
orders in 10.8% (12/111), diastolic/systolic dysfunction in
6.3% (7/111), pulmonary hypertension in 2.7% (3/111), and
other/not speciﬁed in 7.2% (8/111). At M12 and M24,
echocardiogram was performed in 8.3% of patients (13/157
and 9/109, respectively), with 4 and 5 patients having
abnormal results, respectively. Two patients had repeat
echocardiograms at M12 and M24. Of interest, a total of 39
patients had both an echocardiogram and a polysomnogram
at baseline. Of the patients with both studies (n= 39), 19
had an abnormal echocardiogram at baseline. For these
patients with an abnormal echocardiogram, 94.7% (18/19)
had a sleep study showing sleep apnea compared to 11.1%
(1/19) without sleep apnea (p= 0.02, Fisher’s exact test).
Screening for gallbladder stones: gallbladder
sonography
Of the 18.7% of patients (45/241) who had gallbladder
sonography results recorded at enrollment, 60% (27/45) had
abnormal ﬁndings (Fig. 1c). Abnormalities included gall-
stones in 17.8% (8/45) (small in 7, large in 1), sludge in
24.4% (11/45), and other abnormalities in 33.3% (15/45) of
patients. At M12, 3.2% of patients (5/157) had gallbladder
sonography, with 2 patients having abnormal ﬁndings
(other abnormalities). At M24, 5.5% of patients (6/109) had
gallbladder sonography, with 5 having abnormalities,
including 3 patients each with gallstones (small in 2, large
in 1) and other abnormalities.
Screening for colon polyps: colonoscopy
Approximately half (48.1%, 116/241) of patients had
colonoscopy results recorded at enrollment, and the 65
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Table 1 Patient characteristics and comorbidities in acromegaly patients in the SODA study at enrollment
Characteristic/comorbiditya Male
(n= 116)
Female
(n= 125)
All patients
(N= 241)
p-value
Age, years; mean ± SD (range) 47.4 ± 13.5
(17–77)
52.1 ± 15.0
(13–86)
49.8 ± 14.4
(13–86)
0.011
Cardiovascularb 53 (45.7) 64 (51.2) 117 (48.6) 0.392
Arterial hypertension 49 (42.2) 60 (48.0) 109 (45.2)
Coronary artery disease 7 (6.0) 7 (5.6) 14 (5.8)
Peripheral edema 4 (3.5) 4 (3.2) 8 (3.3)
Congestive heart failure 3 (2.6) 2 (1.6) 5 (2.1)
Angina pectoris 3 (2.6) 1 (0.8) 4 (1.7)
Arrhythmias 3 (2.6) 0 3 (1.2)
Cardiomyopathy 3 (2.6) 1 (0.8) 4 (1.7)
Myocardial infarction 1 (0.9) 1 (0.8) 2 (0.9)
Hypopituitarismb 66 (56.9) 40 (32.0) 106 (44.0) <0.001
TSH deﬁciency 37 (31.9) 37 (29.6) 74 (30.7)
Gonadotropin deﬁciency 57 (49.1) 9 (7.2) 66 (27.4)
ACTH deﬁciency 18 (15.5) 10 (8.0) 28 (11.6)
ADH deﬁciency 3 (2.6) 2 (1.6) 5 (2.1)
Arthralgia/arthritis 42 (36.2) 48 (38.4) 90 (37.3) 0.725
Lipid abnormalities 37 (31.9) 43 (34.4) 80 (33.2) 0.680
Diabetes mellitus 23 (19.8) 38 (30.4) 61 (25.3) 0.059
Carpal tunnel syndrome 20 (17.2) 18 (14.4) 38 (15.8) 0.545
Malignanciesb 6 (5.2) 20 (16.0) 26 (10.8) 0.007
Thyroid carcinoma 1 (0.9) 5 (4.0) 5 (2.1)
Breast 0 4 (3.2) 4 (1.7)
Skin (melanoma, 2; basal cell carcinoma, 1;
skin malignancy not speciﬁed, 1)
2 (1.7) 2 (1.6) 4 (1.7)
Brain (brain cell glioma, 1; glioblastoma, 1;
meningioma, 1)
0 3 (2.4) 3 (1.2)
Blood (Burkitt lymphoma, 1; lymphoma, 1) 1 (0.9) 1 (0.8) 2 (0.8)
Prostate 2 (1.7) 0 2 (0.8)
Mandibular 1 (0.9) 0 1 (0.4)
Lung 1 (0.9) 0 1 (0.4)
Cervix uteri 0 1 (0.8) 1 (0.4)
Psychosocialb 6 (5.2) 15 (12.0) 21 (8.7) 0.060
Depression 5 (4.3) 10 (8.0) 15 (6.2)
Anxiety 1 (0.9) 8 (6.4) 9 (3.7)
Cerebrovascular (stroke) 4 (3.5) 5 (4.0) 9 (3.7) 1.000c
Osteopenia/osteoporosis 4 (3.5) 5 (4.0) 9 (3.7) 1.000c
Kidney stones 3 (2.6) 1 (0.8) 4 (1.7) 0.354c
Pancreatitis 1 (0.9) 2 (1.6) 3 (1.2) 1.000c
Data are given as n (%) unless otherwise noted; p-values for comparisons between male and female patients are determined by chi-square unless
otherwise noted
aIncludes comorbidities assessed at enrollment and those listed in patient medical history
bNot mutually exclusive; number of patients with individual comorbidities in a category (bold) may be larger than the number in the overall
category. TSH deﬁciency does not include primary thyroid disease.
cp-value determined by Fisher’s exact test
ACTH adrenocorticotropic hormone, ADH antidiuretic hormone, TSH thyroid-stimulating hormone
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patients with colonoscopy dates recorded had one within ~3
years of enrollment. Abnormalities were found in 46.6%
(54/116) (Fig. 1d), including polyps in 35.3% (41/116) of
patients and other abnormalities in 12.1% (14/116) of
patients. At M12, 8.9% of patients (14/157) had colono-
scopy, with 5 patients showing abnormalities, including 3
patients with polyps and 2 patients with other abnormalities.
At M24, colonoscopy was performed in 12.8% (14/109) of
patients, with 6 showing abnormalities, including polyps in
6 patients and other abnormalities in 1 patient. No cancers
were indicated in any of the abnormal ﬁndings.
Glucose homeostasis and biochemical control:
diabetes and HbA1c
HbA1c was measured in 48/157 patients (30.6%) at M12
and 45/109 (41.3%) at M24 (Fig. 1e). DM patients were
analyzed for HbA1c in 51.2% (22/43) at M12, and 71.0%
(22/31) at M24, and for non-DM patients in 22.8% (26/114)
at M12, and 29.5% (23/78) at M24. Mean HbA1c levels
among all patients with available data were similar at M12
and M24 within each DM and non-DM group. Within each
DM and non-DM group, the proportion of patients with
reported HbA1c <5.7%, 5.7%–6.4%, and ≥6.5% at M12 and
M24 were also similar (Fig. 2). A sensitivity analysis was
conducted to ascertain the impact of pegvisomant on glu-
cose control in the patients treated with lanreotide. In dia-
betic patients (n= 22), none were receiving pegvisomant,
so no comparative analysis was possible. In non-diabetic
patients (n= 23), only 3 patients were receiving con-
comitant pegvisomant with 66.7% (n= 2/3) reporting a
HbA1c between 5.7%–6.4%, compared to 65.2% (n= 15/
23) of those not receiving pegvisomant reporting a HbA1c
in the same range. Also within each DM and non-DM
group, the proportions of biochemically controlled patients
reported within each HbA1c level at M12 and M24 were
similar (Fig. 3).
Biochemical control was reported among the majority of
all patients with available data in the DM and non-DM
groups at M12 and M24 (Fig. 4). Though the proportion of
patients achieving IGF-1 control did not differ between DM
and non-DM at enrollment and M12, the study revealed
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lower rates of IGF-1 <ULN in the DM vs non-DM group at
M24 (p= 0.033).
There were no differences between the DM and non-DM
groups in proportion of patients achieving GH ≤2.5 µg/L at
M12 and M24, and GH <1.0 µg/L at M12 and M24 (Fig. 4).
Similarly, no differences were revealed in biochemical
control of both IGF-1 and GH levels in the DM vs non-DM
group.
Mean LAN 28-day dose equivalent use did not differ
between the DM and non-DM groups at M12 and M24 (Fig.
5). A greater proportion of DM vs non-DM patients
received LAN 120 mg at M24 (p= 0.027). Reported LAN
extended dosing interval (EDI) use did not differ between
the DM and non-DM groups at M12 and M24. There was
no signiﬁcant difference in IGF-1 control between LAN
mono- and combination therapy except in non-DM patients
at M12, where those receiving LAN monotherapy achieved
signiﬁcantly better IGF-1 control vs combination therapy
(44/54, 81.5% vs 17/30, 56.7%; p= 0.015).
Patient deaths
AEs recorded during the 2-year study period have been
reported [18]. Four patients (2 male, 2 female) died during
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the 2-year observation (n= 1 each, congestive heart failure,
heart and respiratory failure, cardiac arrest, and not other-
wise speciﬁed); all deaths were considered by the investi-
gator to be unrelated to treatment. Comorbidities among
these 4 patients included diabetes in 1, hypertension in 4,
and hyperlipidemia in 2. None of the patients had ACTH
deﬁciency.
Discussion
In keeping with guidelines and consensus statements on the
diagnosis and treatment of acromegaly-associated comor-
bidities [2, 6, 7], this report examined the frequency of
monitoring for comorbidities and described the ﬁndings in a
cohort of patients with acromegaly from the SODA registry.
The frequency of optional testing and comorbidity screen-
ing recorded at enrollment, 1, or 2 years was low overall,
potentially reﬂecting the ongoing challenges and geo-
graphic differences in managing this population of patients.
Approximately 50% or fewer of patients had results from
sleep studies, echocardiograms, gallbladder sonographies,
or colonoscopies during study enrollment, and overall
follow-up was infrequently reported during the 2-year
observation period despite abnormal test results in some
patients at enrollment. The reasons for the low frequency of
testing for comorbidities are not exactly clear, but may
involve differences in assessment practices for patients with
a history of acromegaly vs patients at the time of initial
diagnosis. Also, practitioners may not be performing certain
follow-up assessments if a patient with a history of acro-
megaly does not also have a history of the comorbid con-
dition. Furthermore, if a patient achieves and sustains target
biochemical treatment goals, they may not be perceived of
as being at an increased risk for some of the associated
comorbid conditions, even though evidence has shown that
some potentially severe comorbidities, including arthro-
pathy and sleep apnea, may persist even after long-term
biochemical control of acromegaly [19, 20]. Approximately
two-thirds of the patients enrolled in the SODA study were
recruited from sites in academic medical centers and one-
third were from community private practices [17]. How-
ever, whether the number of recruited patients per study site
was proportional to the volume of acromegalic patients
cared for at a particular location is not known. Therefore, no
conclusions can be made regarding the frequency of testing
for comorbidities and the volume of acromegalic patients
seen in a particular center. Limitations attributed to the
observational study design may have also contributed to the
low frequencies of testing reported. Speciﬁcally, patients
may have had a particular study performed but the result
was either unknown or not recorded in the SODA database
by the investigator. In addition, the timeframe of the SODA
study should be considered, as the study used a data cut-off
of 2014, which was prior to the publication of the most
recent acromegaly management guidelines. It should be
noted, however, that the incidence of comorbidities was
similar and in line with that seen in other observational
studies of patients with acromegaly [21, 22].
Cardiovascular comorbidities, including hypertension
(predominantly diastolic), left ventricular hypertrophy
(LVH), diastolic and systolic dysfunction, arrhythmias,
myocardial infarction, enlarged great vessel diameters, and
valve diseases are highly prevalent in acromegaly and are
considered a major cause of mortality [12, 14–16, 23–27].
Among them, hypertension [16] and cardiomyopathy [24]
are considered the main cardiac risk factors that directly
impact mortality. Three of 4 deaths in SODA resulted from
cardiovascular complications, and all 4 patients had
hypertension. Hypertension in SODA was documented in
almost half (45.2%) of patients at enrollment, consistent
with 47.5% in the US acromegaly registry reported by the
Pituitary Center at Cedars-Sinai Medical Center (CSMC-
PC) [28] but higher than rates documented in other studies,
including registry studies (rates ranging from 22% to
41.3%) [9, 14, 21–24, 29, 30]
The prevalence of different features of cardiomyopathy is
3.3–14.2 times higher in the acromegalic than non-
acromegalic population, with the disease duration as its
major determinant [24, 31]. Guidelines recommend routine
echocardiogram and electrocardiogram at diagnosis and
annually during follow-up, especially in patients who have
evidence of ventricular hypertrophy by electrocardiography
or who are symptomatic, particularly if older [2, 6]. In
SODA, only 3 (1.2%) patients had documented cardio-
myopathy at enrollment based on patient medical histories.
Taking into account 4.3 years as the median time since
acromegaly diagnosis, we can assume that cardiomyopathy
was under-assessed in this cohort of patients. Indeed, just
under half of the patients had an echocardiogram at
enrollment, and very few patients had one at follow-up
visits (<10%), of whom nearly half had abnormal ﬁndings.
These data suggest that, in real-world practice, guideline
recommendations are not always followed. However,
according to the Endocrine Society 2014 Acromegaly
Guidelines, the role of pretreatment echocardiogram has not
been deﬁned; rather, thorough cardiac evaluation may be
indicated by suggestive clinical ﬁndings, particularly in
perioperative patients [6]. Also, according to a cardiac MRI
study, patients with active acromegaly might have a lower
(5%) prevalence of LVH than previously reported using
echocardiogram [32].
Sleep apnea, primarily obstructive, is a frequent comor-
bidity in acromegaly due to soft tissue thickening and
edema of the tongue, pharynx, and upper airways, with a
reported prevalence of 25%–60% [5] and ~69% [6].
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Although biochemical control of acromegaly usually
improves sleep apnea, it has been shown to persist in ~40%
of biochemically controlled patients [6, 33]. Guidelines
recommend an annual Epworth Sleepiness Scale or sleep
study during follow-up of acromegaly [2–4, 6]. Less
than one-third of patients had completed a sleep study at
SODA enrollment, and very few (<3%) had entered
a sleep study at follow-up visits. At enrollment, the majority
of tested patients had sleep apnea (79.2%), consistent with
other reports [33–35], although the CSMC-PC and
ACROSTUDY reported signiﬁcantly lower (22.5% and
17%, respectively) prevalence of sleep apnea [22, 28].
However, these numbers are not strictly comparable,
since symptomatic patients were more likely to get sleep
studies, and thus the true prevalence may not be reﬂected.
Also, the SODA database did not distinguish between
obstructive or central sleep apnea. Nonetheless, given
that sleep apnea is independently associated with hyper-
tension and cardiovascular disease [33, 34] and proposed to
account for up to 25% of the excess mortality in untreated
acromegaly [33], there may be potential for improved out-
comes in acromegaly patients if sleep apnea screening is
increased.
The frequent prevalence of DM in SODA patients
(25.3%), along with older-age, higher-BMI, and higher
coexistence of hypertension and statin use in DM vs non-
DM patients noted in the previous 2-year SODA analysis
[18], were ﬁndings similar to those reported in several other
studies [6, 9, 22] and registries [21, 28, 29, 36]. Hyper-
glycemia at diagnosis and ongoing SRL treatment are
independent predictive factors of persistent or new glucose
abnormalities during follow-up [37]. In addition, patients
with comorbid DM are reported to have a lower survival
rate than patients without DM [38]. Therefore, all patients
with acromegaly should be tested for glucose intolerance
and DM, appropriately treated, and followed up as indicated
for these conditions. Guidelines recommend an oral glucose
tolerance test at diagnosis, fasting blood glucose every
6 months (particularly in uncontrolled disease and during
SRL therapy), and HbA1c every 6 months if diabetes is
present [2–4, 6]. In SODA, less than half of patients had
HbA1c results reported after 1 and 2 years of LAN therapy.
Lowering GH levels improves glycemic control and
increases insulin sensitivity in acromegaly; however, SRL
therapy may exert variable effects on glucose metabolism,
with worsening due to inhibition of insulin secretion and
improvement due to improved insulin sensitivity with
acromegaly control [39, 40]. Although the number of
patients with reported HbA1c levels in this SODA analysis
were small, similar proportions of patients were reported in
each HbA1c level at M12 and M24 within each DM and
non-DM subgroup. These ﬁndings support other reports of
the relatively minor impact of SRLs on glucose homeostasis
[39], in particular LAN [41, 42], which is less detrimental to
diabetes than the next-generation SRL pasireotide [43].
Reported biochemical control rates were similar among
patients at M12 and M24, independent of glucose home-
ostasis levels. No signiﬁcant differences between DM and
non-DM groups were observed in patients who achieved
both ≤2.5 µg/L and <1.0 µg/L GH control after 1 and 2 years
of treatment. Conversely, the data revealed higher rates of
IGF-1 <ULN in non-DM vs DM patients after 2 years of
treatment. The similar mean LAN 28-day dose equivalent
and LAN EDI use, and higher use of the 120-mg LAN dose
among DM vs non-DM patients, suggests that inadequate
LAN dosing would not account for the higher IGF-1 levels
in the DM group at M24. One likely explanation is the
hyperinsulinism in the DM group, which enhanced synth-
esis of IGF-1 through upregulation of hepatic GH receptors
[17, 44, 45]. The disconnect between the similar GH levels
in DM vs non-DM patients and the difference in IGF-1 may
also be explained by the effect of obesity [45] and hyper-
insulinism both increasing hepatic GH sensitivity [46] and
increasing free fatty acids, which suppress GH release [47].
These ﬁndings are in agreement with another recent analysis
of SODA data, which indicated that more obese vs non-
obese patients achieved GH <1.0 µg/L after both 1 and 2
years of LAN treatment [18]. Notably, this trend of GH
control was opposite to IGF-1 control. These data are in line
with those of Matta et al [48], who report metabolic syn-
drome markers such as higher fasting blood glucose and
systolic blood pressure, in treated patients with acromegaly
with a high IGF-1 and GH <1 µg/L.
In some studies, colon polyps and/or cancer have been
reported to occur more frequently in acromegaly than in the
general population, although data from other studies have
not supported this association [49, 50]. There is general
agreement, however, that early colonoscopy screening and
regular surveillance is justiﬁed [38, 49, 51–54]. The
Screening Guidelines for Colorectal Cancer and Polyps in
Acromegaly [52] recommend regular colonoscopic screen-
ing, starting at 40 years of age, with frequency of repeat
colonoscopy depending on ﬁndings at original screening
and acromegaly activity. Almost half of SODA patients had
undergone a colonoscopy by enrollment, many within 3
years, and 35.3% had polyps. These ﬁndings are higher than
in other studies [9, 10, 55] and in the Belgian (27.2%) [21]
and CSMC-PC (20.0%, polyps or colon cancer) [28]
registries. Follow-up colonoscopies were recorded in fewer
numbers of SODA patients.
Although the impact of acromegaly and its control on
neoplasia risk and mortality are controversial [6, 8, 27], the
presence of cancer and the last IGF-1 level are considered
signiﬁcant mortality predictors in acromegaly [9, 12, 38].
Malignancies of various systems were reported in 10.8% of
SODA patients at enrollment, which is consistent with
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10.5% in the Belgian registry [21]. Thyroid cancer is a
commonly reported cancer in acromegaly[6, 9], followed by
breast, lung, ovarian, and lymphoma [9]. Consistent with
these reports, thyroid, skin, and breast were the most
common cancer types in the SODA cohort, followed by
brain, blood (lymphoma), and prostate.
Hypopituitarism in acromegaly may develop due to
tumor compression or as a result of surgical or radiation
treatment. Acromegaly guidelines recommend assessing for
hypopituitarism and adequate replacement of adrenal,
gonadal, and thyroid insufﬁciency; patients who receive
radiotherapy need lifelong monitoring of pituitary function
[2, 4, 6]. In SODA, 44.0% of enrolled patients presented
with pituitary hormone deﬁciencies, which is higher than
the rates reported in several European registries [21, 30, 56].
Similar to the German registry [56], pituitary insufﬁciency
was more commonly reported in males compared to
females. The prevalences of TSH and gonadotropin deﬁ-
ciencies were higher in SODA than in the German registry
[56], CSMC-PC registry [28], and ACROSTUDY [22].
Interestingly, as in the German registry [56], gonadotropin
deﬁciency in SODA was more commonly reported in males
(49.1%) vs females (7.2%). The cause for this apparent
gender difference is unknown but it is important to consider
in registry studies that it may be due to ascertainment bias
or potentially less rigorous documentation of gonadal status
in women. This gender difference does not appear to be
related to tumor size, surgery, or radiation exposure as there
were no gender differences noted for these variables in
SODA [18]. ACTH deﬁciency in SODA (11.6%) was
similar to the German registry (11.8%) [56], but lower than
in the CSMC-PC registry (14.9%) [28] and ACROSTUDY
(15%) [22]. ACTH deﬁciency can lead to adrenal crisis
during acute illness and may cause adverse metabolic
effects due to chronic supra-physiological glucocorticoid
replacement, which are associated with increased mortality
in patients with acromegaly [2, 27, 56, 57]. None of the 4
patients who died in SODA had ACTH deﬁciency.
Gallbladder stones were present in 17.8% of SODA
patients with a gallbladder sonography performed at
enrollment, which falls between the rates reported in the
ACROSTUDY (7%) [22] and Belgian registry (23.4%)
[21]. Of note, gallbladder sonography was performed in
only 18.7% of SODA patients. The Endocrine Society
guideline does not suggest routine abdominal ultrasound to
monitor for gallstone disease in a patient receiving an SRL
[6]; however, ultrasound should be performed if a patient
has signs and symptoms of gallstone disease. In SODA, the
frequency of gallbladder ultrasound was relatively low
throughout the observation period, which could be in part
because the study protocol excluded patients with sympto-
matic, untreated biliary lithiasis. Moreover, a retrospective
case cohort study of 31 consecutive newly diagnosed
patients with acromegaly revealed a signiﬁcantly increased
prevalence of gallbladder polyps compared with a control
group [58].
Given that SODA is an observational study, hetero-
geneity of data collection across centers is an inherent
limitation, in addition to the fact that patients in SODA were
enrolled at different stages of disease and treatment. Follow-
up in observational studies is generally not as active or as
standardized as in randomized trials; therefore, ascertain-
ment of outcomes may be incomplete or inaccurate. The
optional studies recorded in the database may not represent
a completely accurate account of all the studies actually
performed due to the possibility of under-reporting.
Although registries are typically more generalizable to ‘real
world’ practice because of their observational design, entry
into a registry may not be as strictly monitored compared
with randomized trials. This may weaken the general-
izability of ﬁndings obtained from analysis of registry data.
The subgroup comparisons were also limited by small
sample sizes in some instances.
In conclusion, this analysis of acromegaly patients from
the observational SODA registry found less frequent real-
life monitoring of comorbid conditions than recommended
by recent treatment guidelines. Additional prospective
analysis will be needed to further identify and address
potential barriers to managing acromegaly-associated
comorbidities and the impact of screening on survival.
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